Demographic, clinical, and laboratory participant characteristics in SMC and non-SMC population.

<p>Demographic, clinical, and laboratory participant characteristics in SMC and non-SMC population.</p

Prevalence of molecular markers of resistance to sulphadoxine, pyrimethamine and amodiaquine at baseline and post-SMC in the SMC population.

<p>Prevalence of molecular markers of resistance to sulphadoxine, pyrimethamine and amodiaquine at baseline and post-SMC in the SMC population.</p

Prevalence of molecular markers of resistance to sulphadoxine, pyrimethamine and amodiaquine at post-SMC in the SMC population <i>vs</i>. concurrent Non-SMC patient population.

<p>Prevalence of molecular markers of resistance to sulphadoxine, pyrimethamine and amodiaquine at post-SMC in the SMC population <i>vs</i>. concurrent Non-SMC patient population.</p

Prevalence of molecular markers of resistance to sulphadoxine, pyrimethamine and amodiaquine at baseline and post intervention period in Non-SMC patient population.

<p>Prevalence of molecular markers of resistance to sulphadoxine, pyrimethamine and amodiaquine at baseline and post intervention period in Non-SMC patient population.</p

Additional file 1 of The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone

Additional file 1: Table S1. Number of clinical malaria episodes by time since vaccination in each year of the study, using 90-day periods (as used in the Piecewise Cox regression models). Table S2. Number of clinical malaria episodes by time since vaccination in each year of the study, using 60-day periods (not used in the Piecewise Cox regression models, but provided to show the declining incidence of malaria further into the dry season). Table S3. Number and percentage of children who were scheduled to receive SMC, received SMC, and received all daily SMC doses (full SMC) over the course of the study. Figure S1. Observed hazard function and Cumulative hazard function, and the fitted cumulative hazard and estimated protective efficacy from flexible parametric survival models used to estimate vaccine efficacy in each year of the study. Figure S2. Protective Efficacy of SMC in the first 21 days and first 30 days after SMC received, by cycle. Figure S3. Protective Efficacy by time since the final SMC cycle in each year. Figure S4. Comparison of the SMC protective efficacy profile obtained in this study with the profile estimated for an earlier placebo-controlled trial of SMC